Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Venetoclax in Combination With ASTX727 in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Newly Diagnosed Elderly Patients With AML Who Are Not Candidates for Intensive Chemotherapy

Next Previous
X
Search
Trial Profile

A Phase 2 Study of Venetoclax in Combination With ASTX727 in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Newly Diagnosed Elderly Patients With AML Who Are Not Candidates for Intensive Chemotherapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cedazuridine/decitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results (n=52, 42 in the FL and 10 in the R/R cohorts) evaluating the efficacy and safety of ASTX727 plus venetoclax in the frontline (FL) and relapsed-refractory, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 05 Sep 2023 Planned End Date changed from 15 Oct 2023 to 15 Oct 2024.
    • 05 Sep 2023 Planned primary completion date changed from 15 Oct 2023 to 15 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top